Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily Dialogue, 8/15/11, a classic risk-on day as advancers pass decliners

The 6 W’s: Who, what, where, when, why and what of it…

Most European stocks are advancing after 3 weeks of losses left equities near the cheapest in 2 years. Global markets are stabilizing after a week of record swings in US stocks

A higher futures opening on Monday after data showed a smaller-than-expected contraction in the Japanese economy ahead of US reports on the manufacturing and housing sectors. Thus, US stocks opened sharply higher on a spate of corporate deals. The Dow gained 120.98 points to 11,390.00. The S&P advanced 13.62 points to 1,192.43. The NASDAQ added 25.86 points to 2,533.84.

The NASDAQ is now UP +22.62 (+0.90%) to 2,532.51. The Dow is also UP +150.65 (+1.34%) to 11,419.67.  The DOW is still UNDER 12,000.

 

Regenerative medicine/stem cell universe shares on 8/15/11 are “moving with small volumes as earnings populate the universe … keep your eye on cash positions.

Questions … will this low volumes rally … continue … or is it a seller’s boycott … as conviction remains questionable?

Not to be a “said-so” or “told-you so” person  but Cytori (NASDAQ:CYTX) is up $0.46 – look for better highs and regaining its former altitude; NeoStem (AMEX: NBS) is up $0.081 as earnings are out, not bad,  revenues, still there.  I consider CYTX and NBS, appreciation plays versus value traps however; everything is still speculative post the sell-off.  NBS ($0.716) and CYTX ($3.74) are strong LONG(s) at these prices.

The RegMed universe has been trading on pure emotion and lack of visibility. So, red flags aside, the smoking gun has been fired. Sentiment is still negative as the markets are in turmoil but, quoting from one past RegMed Daily Dialogue (8/8/11), “the blood is already in the street”. The declines withstanding, are you an investor or a trader?

Should we now put forth a measurement tool … measuring against the … Newest Normal?

 

Mid-Day Movers … Advanced Cell Technology (ACTC.OB), Aastrom (ASTM), Athersys (NASDAQ:ATHX), BioMimetic (NASDAQ:BMTI), BioTime (AMEX: BTX), Cytori (CYTX), Geron (NASDAQ:GERN), Neuralstem (AMEX: CUR), NeoStem (AMEX: NBS), Opexa (OPXA), Osiris (NASDAQ:OSIR), Pluristem (NASDAQ:PSTI), Tengion (TNGN) and ThermoGenesis (NASDAQ:KOOL)

 

What’s new in the regenerative medicine/stem cell market … EARNINGS … still announcing

Key indicators: Cytori (CYTX) insiders are buying, Marc Hedrick (President) – 2,500 shares;   Ronald Henriksen (Director) – 2,000 shares and Mark Saad (NASDAQ:CFO) -6500 shares and Lloyd Dean (Director) – 7500 shares

NeoStem (AMEX:NBS) Q2/11 Results: A net loss of $10.77M or $0.13 per share as compared to Q2/10 of $5.4M or $0.11 per share versus a Q1/11 net loss of $9.69M or $0.14 per share. Cash and cash equivalents at 6/30/11 were $4.85M while receivables were $7.3M plus NBS completed an underwritten offering of 13.75M units at a purchase price of $1.20 per unit, with each unit consisting of one share of Common Stock and a 5 year warrant to purchase 0.75 of a share of common stock at an exercise price of $1.45 per share NBS received gross proceeds of $16.5M 

UK scientists get funding for prostate cancer stem cell research: Researchers at the University of York have received about $3.5M in funding from the charity Yorkshire Cancer Research to identify molecular mechanisms that allow prostate cancer stem cells to metastasize and develop resistance to treatments. They hope the study can enable them to develop a new class of drugs that zero in on stem cells causing the disease. The bottom line, Professor Maitland said his team would look at the DNA sequence of prostate cancer stem cells to determine for the first time what is missing from the sequence. He said: “We will also further develop our laboratory models of prostate cancer to test current and new treatments including radiation and drugs on cancer stem cells. Using these methods they hope to identify survival mechanisms of the cancer stem cells and develop a new generation of treatments to undermine and kill them

Tengion Board of Directors Update:  TNGN has appointed Diane Jorkasky, MD, who recently joined Endo Pharmaceuticals (NASDAQ:ENDP) as SVP, Clinical Development and CMO, to its BOD. Brenda Gavin, DVM, Managing Partner at Quaker BioVentures, is stepping down from the Board of Directors after 5 years of service. Dr. Jorkasky is the enterprise-wide CMO of Endo Pharmaceuticals and a member of the senior R&D management team.   Prior to joining Endo in 2011, she was Chief Development and Medical Officer at Aileron Therapeutics and previously held a variety of vice president level positions over nearly a decade with Pfizer Global R&D where she led global clinical research science and operational groups. Dr. Jorkasky began her career at SmithKline Beecham, where she served as Vice President of Clinical Pharmacology for North America. She received her B.A. in Chemistry at the College of Wooster and her M.D. from the University of Pennsylvania and she is board-certified in nephrology, internal medicine and clinical pharmacology. The bottom line, change was and is needed.